We would love to hear your thoughts about our site and services, please take our survey here.
Riesgo
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential of the pre|CISIONTM technology.
AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed.
A number of tumour biopsies obtained from patients in different cohorts have also been analysed in order to confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue. This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same timepoint.
Viking
I see they’ve had enough of you on the SYM board.
A little tip, so have we.
Game playing, brucies bonus?
Few delayed trades??
MMs playing games here and holding the price down. Delayed trades of that amount I’m amazed we were so in the red today.
Blue tomorrow.
Terry
How many shares do you have?
I can answer that, if you want?
Pretty sure they are sells at 159.50.
https://www.asktraders.com/analysis/avacta-shares-have-risen-43-ytd-so-why-are-they-pulling-back/
Slightly incorrect in some instances of this article, but the word is getting out.
MB
Do you realise that if that was the case someone would be looking at jail!
Drrr
DITRA
Agreed
In the recent interview he gave I made a few notes:
‘Data is unequivocal, it is being released in the tumour at double the normal level.
Delighted it is being released at significant levels analysing biopsies across several cohorts in all biopsies. Safety profile very favourable and positive but need to find MTD.
Next step higher dose concluded by this half year. Next part is dose expansion focus 1/2 cancer types 20 patients for soft tissue sarcoma begins asap later this year. In UK and 2 places being lined up in the US.
Results very promising very encouraging therapeutic level and safety too. ‘
Not my words, but the man in the know!
IMO
The resident shorter is in town.
Ries
I expect a further update via RNS prior to 23/2/23.
Otherwise, why the invite? To repeat the info they already know from the last RNS.
Make your own mind up.
GL
Viking
As per the last RNS.
‘will host a Science Day for City analysts and fund managers on 23rd February 2023 to discuss recent progress within the Company's Therapeutics Division and hear from selected key opinion leaders in the field of oncology.’
If there is nothing else to share, then why the invite?
GLA
Kenny
Your second post is almost as good as your first:
‘Evening chaps and chapettes, I keep seeing people raging on about this share and just wondered if someone can fill me in on what all the excitement is all about? looking to potentially invest as im all cash at the moment. Any timelines for expected news?’
Just saying….
Lower price top up!
At this price
DYOR
Maybe we should all put this message on every day and when we have a red day then say told you so.
Great post lick
Revoy
Don’t listen to people on here for advice.
DYOR and listen to AS in recent feedback and consult the informative RNS.
That should explain everything.
GL
More media support for our positive news.
Onwards…